ALKS — Alkermes plc

Is ALKS overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Neutral As of October 3, 2026

Alkermes plc (ALKS) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $41.75. The rating moved from Oversold to Neutral on October 2, 2026.

AI analysis

Alkermes plc combines recurring commercial revenue from marketed specialty products with a pipeline that could generate mid‑to‑longer‑term upside if clinical readouts and regulatory outcomes are favorable. Current market conditions are cautious, with policy headwinds (drug‑pricing negotiations) and increased therapeutic competition exerting downward pressure on valuation and pricing leverage. The company’s near‑term stability benefits from product cash flows, but growth depends on successful execution of clinical programs, protecting exclusivities, and managing payer dynamics. Watch upcoming clinical/regulatory milestones, cash runway metrics, and any payer‑pricing developments as primary determinants of directional moves.

Key factors

  • Established commercial revenue stream from marketed specialty products provides recurring cash flow and supports near-term operations.
  • Pipeline assets and late‑stage clinical readouts could be meaningful catalysts if positive, aligning with investor appetite for select late‑stage biologics.
  • Exposure to policy and payer pressure (Medicare negotiation and pricing scrutiny) may compress pricing power for specialty therapies.
  • Macroeconomic risk-off sentiment and cooling IPO/healthcare-risk appetite reduce near-term capital-market optionality and valuation support for biotech names.
  • Competitive dynamics in therapeutic areas relevant to Alkermes (novel entrants, combo regimens) could pressure market share and pricing over time.
  • Recent SEC filing activity is neutral — no major transactions or disclosures that materially change near-term fundamentals or investor perception.

Risks

  • Medicare drug‑price negotiation and broader affordability policies that could reduce net prices and volumes for high-cost therapies.
  • Clinical trial failures or missed regulatory milestones for pipeline products, which would materially reduce upside potential.
  • Revenue concentration on a limited set of products; loss of exclusivity or competitive substitution would harm top-line stability.
  • Manufacturing, supply‑chain, or quality issues that disrupt product availability and revenue recognition.
  • Liquidity and financing risk if R&D burn continues and capital markets remain constrained for healthcare issuance.
  • Increased competition from GLP‑1/amylin combos and other novel modalities that alter treatment paradigms and pricing dynamics.
  • Adverse legal or patent outcomes that could affect exclusivity or create unexpected liabilities.

See today's live rating, score and targets

Members see the live hourly rating for ALKS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.